OncoSec Announces Pricing of $3.5 Million Public Offering

PENNINGTON, N.J. and SAN DIEGO, Nov. 30, 2022 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient’s own immune system to target and…

Click here to view original post